Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patients
Latest Information Update: 14 May 2016
At a glance
- Drugs Erlotinib (Primary) ; Curcumin
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 14 Mar 2016 Status changed from not yet recruiting to discontinued.
- 10 Apr 2014 New trial record